Research analysts at Leerink Partnrs lifted their Q1 2025 earnings estimates for shares of Beam Therapeutics in a research ...

Analysts at Leerink Partnrs issued their FY2024 earnings estimates for shares of Shattuck Labs in a report released on Monday ...

Fintel reports that on March 21, 2025, Leerink Partners downgraded their outlook for Elevation Oncology (NasdaqGS:ELEV) from ...

Leerink Partners analyst Thomas Smith reiterated a Buy rating on Immunovant (IMVT – Research Report) yesterday and set a price target of ...

Leerink downgraded Elevation Oncology (ELEV) to Market Perform from Outperform with a price target of $1, down from $9, after the company ...

Fintel reports that on March 17, 2025, Leerink Partners initiated coverage of Shattuck Labs (NasdaqGS:STTK) with a Outperform ...

Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting ...

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today ...

I think we'll get started. Hi, everyone. My name is Daina Graybosch. I'm a Senior Analyst here at Leerink Partners, covering largely immuno-oncology and also Gilead, which is broader than immuno ...

On Tuesday, 11 March 2025, MacroGenics (NASDAQ: MGNX) presented at Leerink’s Global Healthcare Conference 2025. The company showcased its robust pipeline of cancer therapeutics and strategic ...

Leerink Partners 2025 Global Healthcare Conference Call March 11, 2025 8:00 AM ET. Company Participants. Ryan Crowe - SVP, IR & Strat ...

On Tuesday, 11 March 2025, Novocure Ltd (NASDAQ: NVCR) presented at Leerink’s Global Healthcare Conference 2025, outlining its strategic focus on expanding Tumor Treating Fields (TTFields ...